Laurel A Beckett1, Michael C Donohue2, Cathy Wang3, Paul Aisen4, Danielle J Harvey3, Naomi Saito3. 1. Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA. Electronic address: labeckett@ucdavis.edu. 2. Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, CA, USA. 3. Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA. 4. Department of Neurosciences, University of California, San Diego, CA, USA.
Abstract
INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study designed to characterize the trajectories of biomarkers across the aging process. We present ADNI Biostatistics Core analyses that integrate data over the length, breadth, and depth of ADNI. METHODS: Relative progression of key imaging, fluid, and clinical measures was assessed. Individuals with subjective memory complaints (SMC) and early mild cognitive impairment (eMCI) were compared with normal controls (NC), MCI, and individuals with Alzheimer's disease. Amyloid imaging and magnetic resonance imaging (MRI) summaries were assessed as predictors of disease progression. RESULTS: Relative progression of markers supports parts of the amyloid cascade hypothesis, although evidence of earlier occurrence of cognitive change exists. SMC are similar to NC, whereas eMCI fall between the cognitively normal and MCI groups. Amyloid leads to faster conversion and increased cognitive impairment. DISCUSSION: Analyses support features of the amyloid hypothesis, but also illustrate the considerable heterogeneity in the aging process.
INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study designed to characterize the trajectories of biomarkers across the aging process. We present ADNI Biostatistics Core analyses that integrate data over the length, breadth, and depth of ADNI. METHODS: Relative progression of key imaging, fluid, and clinical measures was assessed. Individuals with subjective memory complaints (SMC) and early mild cognitive impairment (eMCI) were compared with normal controls (NC), MCI, and individuals with Alzheimer's disease. Amyloid imaging and magnetic resonance imaging (MRI) summaries were assessed as predictors of disease progression. RESULTS: Relative progression of markers supports parts of the amyloid cascade hypothesis, although evidence of earlier occurrence of cognitive change exists. SMC are similar to NC, whereas eMCI fall between the cognitively normal and MCI groups. Amyloid leads to faster conversion and increased cognitive impairment. DISCUSSION: Analyses support features of the amyloid hypothesis, but also illustrate the considerable heterogeneity in the aging process.
Authors: Michael C Donohue; Hélène Jacqmin-Gadda; Mélanie Le Goff; Ronald G Thomas; Rema Raman; Anthony C Gamst; Laurel A Beckett; Clifford R Jack; Michael W Weiner; Jean-François Dartigues; Paul S Aisen Journal: Alzheimers Dement Date: 2014-03-20 Impact factor: 21.566
Authors: R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal Journal: Alzheimer Dis Assoc Disord Date: 1997 Impact factor: 2.703
Authors: L S Schneider; F Mangialasche; N Andreasen; H Feldman; E Giacobini; R Jones; V Mantua; P Mecocci; L Pani; B Winblad; M Kivipelto Journal: J Intern Med Date: 2014-03 Impact factor: 8.989
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182
Authors: Susan M Landau; Mark A Mintun; Abhinay D Joshi; Robert A Koeppe; Ronald C Petersen; Paul S Aisen; Michael W Weiner; William J Jagust Journal: Ann Neurol Date: 2012-10 Impact factor: 10.422
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Li Shen; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2013-08-07 Impact factor: 21.566
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: Jeffrey N Motter; Gregory H Pelton; Kristina D'Antonio; Sara N Rushia; Monique A Pimontel; Jeffrey R Petrella; Ernst Garcon; Michaela W Ciovacco; Joel R Sneed; P Murali Doraiswamy; Davangere P Devanand Journal: Int J Geriatr Psychiatry Date: 2018-07-23 Impact factor: 3.485
Authors: Lucas Arbabyazd; Kelly Shen; Zheng Wang; Martin Hofmann-Apitius; Petra Ritter; Anthony R McIntosh; Demian Battaglia; Viktor Jirsa Journal: eNeuro Date: 2021-07-06
Authors: Michael W Lutz; Donna Crenshaw; Kathleen A Welsh-Bohmer; Daniel K Burns; Allen D Roses Journal: Curr Neurol Neurosci Rep Date: 2016-05 Impact factor: 5.081
Authors: Shannon L Risacher; Wesley H Anderson; Arnaud Charil; Peter F Castelluccio; Sergey Shcherbinin; Andrew J Saykin; Adam J Schwarz Journal: Neurology Date: 2017-10-25 Impact factor: 9.910
Authors: Aina Frau-Pascual; Jean Augustinack; Divya Varadarajan; Anastasia Yendiki; David H Salat; Bruce Fischl; Iman Aganj Journal: Brain Connect Date: 2021-05-27